Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析

◆英語タイトル:Ultragenyx Pharmaceutical Inc (RARE) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH331624FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥28,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥42,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Ultragenyx Pharmaceutical Inc (RARE) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Ultragenyx Pharmaceutical Inc (Ultragenyx) develops novel therapeutics for rare and ultra-rare genetic diseases. It has three marketed products, Mepsevii (vestronidase alfa) is approved for the treatment of adults and children with Mucopolysaccharidosis (MPS) VII (Sly syndrome); Dojolvi (triheptanoin), a highly purified, synthetic, 7-carbon fatty acid triglyceride for patients with long-chain fatty acid oxidation disorders (LC-FAOD) and Crysvita (burosumab), a fully human monoclonal antibody for the treatment of X-linked hypophosphatemia (XLH). Its pipeline includes DTX401 for the treatment of patients with glycogen storage disease type Ia, or GSDIa; UX701 for wilson disease; UX053 for glycogen storage disease type III; GTX-102 for the treatment of angelman syndrome in partnership with GeneTx; and DTX301 for the treatment of ornithine transcarbamylase. It works in partnership with various academic institutes and biotechnology companies to advance its product candidates. Ultragenyx is headquartered in Novato, California, the US.

Ultragenyx Pharmaceutical Inc Key Recent Developments

Feb 11,2021: Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Feb 04,2021: Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update
Jan 11,2021: Ultragenyx reports preliminary 2020 revenue and 2021 revenue guidance for Crysvita in Ultragenyx Territories
Jan 08,2021: Ultragenyx announces progress across broad gene therapy portfolio and positive longer-term Data from multiple phase 1/2 gene therapy studies
Nov 09,2020: Ultragenyx announces plans to build large-scale gene therapy manufacturing facility to support pipeline of therapies for rare diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Ultragenyx Pharmaceutical Inc – Key Facts
Ultragenyx Pharmaceutical Inc – Key Employees
Ultragenyx Pharmaceutical Inc – Key Employee Biographies
Ultragenyx Pharmaceutical Inc – Major Products and Services
Ultragenyx Pharmaceutical Inc – History
Ultragenyx Pharmaceutical Inc – Company Statement
Ultragenyx Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Ultragenyx Pharmaceutical Inc – Business Description
Product Category: Collaboration and License Revenue
Performance
Product Category: Crysvita
Overview
Performance
Product Category: Dojolvi
Overview
Performance
Product Category: Mepsevii
Overview
Performance
Product Category: Royalty Revenue
Performance
Geographical Segment: All other
Performance
Geographical Segment: Europe
Performance
Geographical Segment: North America
Performance
R&D Overview
Ultragenyx Pharmaceutical Inc – Corporate Strategy
Ultragenyx Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
Ultragenyx Pharmaceutical Inc – Strengths
Ultragenyx Pharmaceutical Inc – Weaknesses
Ultragenyx Pharmaceutical Inc – Opportunities
Ultragenyx Pharmaceutical Inc – Threats
Ultragenyx Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 11, 2021: Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update
Feb 04, 2021: Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update
Jan 11, 2021: Ultragenyx reports preliminary 2020 revenue and 2021 revenue guidance for Crysvita in Ultragenyx Territories
Jan 08, 2021: Ultragenyx announces progress across broad gene therapy portfolio and positive longer-term Data from multiple phase 1/2 gene therapy studies
Nov 09, 2020: Ultragenyx announces plans to build large-scale gene therapy manufacturing facility to support pipeline of therapies for rare diseases
Oct 28, 2020: Ultragenyx announces proposed public offering of common stock
Oct 27, 2020: Ultragenyx reports third quarter 2020 financial results and corporate update
Oct 23, 2020: Ultragenyx and Solid Biosciences announce strategic collaboration to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy
Sep 02, 2020: Ultragenyx appoints Mardi C. Dier as Chief Financial Officer
Sep 01, 2020: Ultragenyx expands leadership team and appoints Ernie Meyer as Chief Human Resources Officer
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Ultragenyx Pharmaceutical Inc, Key Facts
Ultragenyx Pharmaceutical Inc, Key Employees
Ultragenyx Pharmaceutical Inc, Key Employee Biographies
Ultragenyx Pharmaceutical Inc, Major Products and Services
Ultragenyx Pharmaceutical Inc, History
Ultragenyx Pharmaceutical Inc, Subsidiaries
Ultragenyx Pharmaceutical Inc, Key Competitors
Ultragenyx Pharmaceutical Inc, Ratios based on current share price
Ultragenyx Pharmaceutical Inc, Annual Ratios
Ultragenyx Pharmaceutical Inc, Annual Ratios (Cont...1)
Ultragenyx Pharmaceutical Inc, Interim Ratios
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Ultragenyx Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Ultragenyx Pharmaceutical Inc (RARE):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • CH&Co Group:企業の戦略・SWOT・財務分析
    CH&Co Group - Strategy, SWOT and Corporate Finance Report Summary CH&Co Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Formula Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Formula Pharmaceuticals Inc (Formula Pharmaceuticals) is an oncology company that develops chimeric antigen receptor (CAR) immunotherapy for oncology and autoimmune diseases. The company’s pipeline products include CIK-CAR.CD19, used as B-lymphocyte surface antigen; CIK-CAR.CD33, used for th …
  • Nestle Australia Ltd:企業の戦略・SWOT・財務情報
    Nestle Australia Ltd - Strategy, SWOT and Corporate Finance Report Summary Nestle Australia Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Gabather AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Gabather AB (Gabather) is a developer of new drug candidates for the treatment of central nervous system diseases. The company spans its expertise in the development of anti-psychotics, anti-depressants and anxiolytics, analgesics, and cognition-enhancing treatments. It offers drug candidate …
  • General Dynamics Land Systems Inc:企業の戦略・SWOT・財務情報
    General Dynamics Land Systems Inc - Strategy, SWOT and Corporate Finance Report Summary General Dynamics Land Systems Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • BioCryst Pharmaceuticals Inc (BCRX):企業の財務・戦略的SWOT分析
    BioCryst Pharmaceuticals Inc (BCRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Hwange Colliery Co Ltd:企業の戦略・SWOT・財務分析
    Hwange Colliery Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Hwange Colliery Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Horizon Discovery Group Plc:企業のM&A・事業提携・投資動向
    Horizon Discovery Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Horizon Discovery Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …
  • Gold Road Resources Ltd (GOR):企業の財務・戦略的SWOT分析
    Summary Gold Road Resources Ltd (GRRL), formerly Eleckra Mines Ltd, is a mining and mineral exploration and development company that offers mining services. The company acquires, explores and develops iron, gold, nickel and mineral deposits properties. Its projects comprise Gruyere project, Yamarna …
  • Teleflex Inc (TFX):企業の財務・戦略的SWOT分析
    Teleflex Inc (TFX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • SAG. Solar GmbH & Co KG-エネルギー分野:企業M&A・提携分析
    Summary S.A.G. Solar GmbH & Co. KG. (S.A.G. Solar), a subsidiary of Shunfeng International Clean Energy Limited, is a manufacturer of photovoltaic systems. The company constructs, installs, operates and integrates solar power plants. It constructs rooftop systems, roof and facade-integrated systems, …
  • Patel Engineering Ltd:企業の戦略・SWOT・財務情報
    Patel Engineering Ltd - Strategy, SWOT and Corporate Finance Report Summary Patel Engineering Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Hyundai Engineering & Construction Co Ltd (000720):電力:M&Aディール及び事業提携情報
    Summary Hyundai Engineering & Construction Co Ltd (Hyundai E&C), a subsidiary of Hyundai Motor Co, is an engineering and construction contracting company. It provides civil and construction works for roads, bridges, harbors, highways and railways. It also undertakes property development of residenti …
  • United Internet AG:企業のM&A・事業提携・投資動向
    United Internet AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's United Internet AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Symetra Life Insurance Company:企業の戦略・SWOT・財務情報
    Symetra Life Insurance Company - Strategy, SWOT and Corporate Finance Report Summary Symetra Life Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Royal Bank of Canada:企業のM&A・事業提携・投資動向
    Royal Bank of Canada - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Royal Bank of Canada Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Ohio State University Comprehensive Cancer Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Ohio State University Comprehensive Cancer Center (OSUCCC), a subsidiary of Ohio State University, is a healthcare institute that offers medical and academic education services. The institute provides education, research, and patient care services. Its services comprise cancer diagnosis, tre …
  • Seaboard Corp (SEB):企業の財務・戦略的SWOT分析
    Seaboard Corp (SEB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Keyera Corp (KEY):企業の財務・戦略的SWOT分析
    Keyera Corp (KEY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Greatship (India) Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Greatship (India) Ltd (GIL), a subsidiary of The Great Eastern Shipping Co. Ltd is an offshore oilfield service provider that offers shipping and transportation services. The company transports crude oil, petroleum products, gas and bulk commodities. It provides offshore logistics and drilli …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆